Pricing and reimbursement of orphan drugs in Italy

被引：0
|
作者：
Lopatriello, S.
Schivazappa, C.
Negrini, C.
Berto, P.
机构：
[1] PBE Consulting, Verona, Italy
[2] PBE Consulting, Milan, Italy
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63221-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A208 / A209
页数：2
相关论文
共 50 条
  • [21] TOP 20 ORPHAN DRUGS AVAILABILITY, PRICING AND REIMBURSEMENT IN SLOVAKIA: 2005-2012 REVIEW
    Babela, R.
    Uraz, V
    Babelova, O.
    Slezakova, Z.
    VALUE IN HEALTH, 2014, 17 (07) : A540 - A541
  • [22] Orphan Drug Pricing and Reimbursement Policies Lacking in EU
    不详
    PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 297 - 298
  • [23] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [24] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [25] ELIGIBILITY OF ORPHAN DRUGS FOR PREFERENTIAL REIMBURSEMENT IN EGYPT
    Fasseeh, A. N.
    Elezbawy, B.
    Korra, N.
    Roushdy, M.
    Seyam, A.
    Hayek, N.
    Rahman, Abdel N.
    Abdelhamid, S.
    Fasseeh, N.
    Saad, A. S.
    Elagamy, A.
    Mahmoud, A.
    Sedrak, A. S.
    Elshazly, K.
    Eldebeiky, M.
    Talaat, M.
    Maher, N.
    Abdelaziz, R.
    Refaat, R.
    Akeel, S.
    Adel, R.
    Khalil, S.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S265 - S265
  • [26] ANTIOSTEOPOROTIC DRUGS AND THEIR REIMBURSEMENT IN ITALY
    Nuti, R.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S57 - S58
  • [27] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
    Mukku, S.
    Pang, F.
    Mcconkey, D.
    VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
  • [28] MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
    Vollmer, L.
    Prada, M.
    Benazet, F.
    Berard, I
    Lopez, N.
    Guterres, S.
    Walzer, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [29] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
    Lee, Jong Hyuk
    Yoo, Seung-Lai
    EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28
  • [30] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
12345